FDA to discuss narcolepsy at patient-focused meeting

FDA will hold a public meeting on Sept. 24 to discuss the impact of narcolepsy and its currently available therapies. The meeting is being held under FDA's Patient-Focused Drug Development initiative, under which the agency is holding public meetings on a range of disease areas to discuss topics including the impact of the disease, the measures of benefit that matter most to patients and the adequacy of existing treatment options. ...